NEW YORK – Although most of the clinical testing and biopharma services Genetron Health currently provides are in the area of advanced cancer genotyping, the firm said this week that its eye is firmly on liquid biopsy testing, especially for early cancer detection and monitoring, as it maps out future technology and commercial development plans for both China and the US.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.